What Canadian GLP-1 users need to know about 'Ozempic face' and emerging cosmetic treatments

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

What is 'Ozempic face' and why is it in the news now?

As of October 2026, major cosmetic companies are actively developing and marketing products aimed at people who experience facial volume loss while taking semaglutide (sold in Canada as Ozempic, approved by Health Canada for type 2 diabetes management, and as Wegovy, approved for chronic weight management). The term 'Ozempic face' refers to the accelerated skin laxity, hollowing of the cheeks and temples, and deepening of facial lines that can follow rapid, significant weight loss on GLP-1 receptor agonists. A Reuters report published October 21, 2026 and carried by CTV News documented how beauty industry players are treating this as a commercial opportunity, with product lines and clinic services specifically positioned for GLP-1 users.

For Canadians on these drugs, the practical question is immediate: if you are losing weight on semaglutide or another GLP-1 medication, should you be worried about your face, and are any of the marketed cosmetic solutions worth pursuing? The short answer is that the facial changes are real and documented by dermatologists, but the cosmetic industry's response is moving faster than the clinical evidence, and Health Canada has not yet issued guidance on any cosmetic or dermatological intervention specifically for GLP-1-related facial changes.

What this means in Canada

Health Canada approved Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) for adults with type 2 diabetes and Wegovy (semaglutide 2.4 mg) for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Both are manufactured by Novo Nordisk. Coverage varies sharply by province: Ontario's OHIP does not cover the drugs themselves, though some private plans do; Quebec's RAMQ covers Ozempic for diabetes but has had ongoing restrictions on Wegovy; British Columbia's PharmaCare and Alberta's AHCIP (Alberta Health Care Insurance Plan) have their own formulary criteria. Canada's national pharmacare framework, still being phased in as of 2026, does not yet uniformly cover GLP-1 agonists for weight management across all provinces.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement specifically on GLP-1-related cosmetic side effects. The Canadian Dermatology Association has acknowledged facial volume loss as a documented consequence of rapid weight loss generally, but has not published GLP-1-specific clinical guidelines as of this writing. Dermatology and plastic surgery clinics in Toronto, Vancouver, Calgary, and Montreal are already seeing patients asking about fillers and skin-tightening procedures after GLP-1-driven weight loss, according to clinician accounts in Canadian media.

Why this matters

The global GLP-1 market has grown at a pace that outstrips clinical guidance in almost every adjacent area. When patients lose 10 to 20 percent of body weight over months rather than years, the face loses subcutaneous fat faster than the skin can retract. Dermatologists describe this as accelerated facial aging: the same process that happens with age-related fat redistribution, compressed into a shorter window. The American Academy of Dermatology has noted that rapid weight loss of any cause can produce these changes, and that hyaluronic acid fillers, collagen-stimulating injectables, and radiofrequency skin-tightening devices are among the options clinicians discuss with patients.

The cosmetic industry's response, as documented by Reuters, is to build product lines that claim to address skin laxity, volume loss, and surface texture changes in GLP-1 users specifically. Some of these are topical skincare products; others involve clinic-based procedures. The concern from a patient-safety standpoint is that marketing is outpacing evidence. There are no randomized controlled trials, as of October 2026, specifically examining cosmetic interventions in GLP-1 users versus other weight-loss populations. The facial changes are not unique to semaglutide; they are a consequence of the weight loss itself.

What Canadian patients should know

If you are taking semaglutide or another GLP-1 receptor agonist and have noticed changes in your facial appearance, a few things are worth knowing before spending money on cosmetic products or procedures.

First, the rate of weight loss matters. Dermatologists generally note that slower weight loss gives skin more time to adapt. If your prescribing physician has flexibility in titration, this is worth discussing, though clinical decisions about dosing should be based on your metabolic health, not cosmetic concerns.

Second, not all cosmetic interventions are equal. Hyaluronic acid fillers (such as Juvederm or Restylane, both available at Canadian dermatology and cosmetic clinics) are Health Canada-approved medical devices for facial volume restoration and have a reasonable evidence base for that indication generally. Radiofrequency and ultrasound skin-tightening devices are also available at Canadian clinics. Topical skincare products marketed specifically for 'Ozempic face' have no regulatory approval for that claim in Canada; Health Canada regulates cosmetic claims, and a product cannot legally claim to treat a medical condition without a Drug Identification Number.

Third, costs are almost entirely out of pocket. Cosmetic dermatology procedures are not covered by provincial health plans. Filler treatments at Canadian clinics typically run CAD $600 to $1,200 per syringe, and multiple syringes are often recommended for significant volume loss. Skin-tightening device sessions can run CAD $500 to $2,000 per treatment.

Canadian telehealth platforms such as Felix (a Canadian men's and weight-management health platform) and Maple (a Canadian virtual care platform) offer GLP-1 prescribing but do not provide cosmetic dermatology services. Science & Humans (scienceandhumans.com), a Canadian hormone and metabolic health platform, similarly focuses on the prescribing side. For cosmetic concerns, patients need a referral to or direct booking with a dermatologist or plastic surgeon. Wait times for dermatology in the public system are long in most provinces; private cosmetic clinics have no wait but charge accordingly.

Limitations and open questions

Several things are genuinely unknown. There are no published clinical trials on whether any specific cosmetic intervention produces better outcomes in GLP-1 users than in people who lost equivalent weight by other means. It is not clear whether continuing on semaglutide while undergoing filler treatment affects filler longevity or distribution, though some clinicians have raised this as a theoretical question given GLP-1 receptors' presence in various tissues.

Health Canada has not issued any advisory or guidance document on cosmetic management of GLP-1-related body changes. The SOGC has not addressed this topic. The Canadian Institutes of Health Research (CIHR) has funded GLP-1 research, but not, as of this writing, in the cosmetic dermatology space.

The cosmetic industry's commercial interest in this population is clear. Whether the products being marketed deliver meaningful results for GLP-1 users specifically, beyond what they would deliver for any patient with facial volume loss, has not been established. Patients should ask any clinician recommending a procedure what evidence base they are drawing on, and whether the recommendation would differ for someone who lost the same amount of weight through diet alone.